Funder: Gilead Sciences
Due Dates: January 30, 2026: Letter of Intent deadline | April 3, 2026: Full application deadline
Funding Amounts: ~$5,000,000 total available; typical awards up to $500,000 (higher amounts require pre-approval); up to 18 months per project.
Summary: Supports implementation research on twice-yearly Lenacapavir for HIV prevention in high-need populations within 11 eligible countries.
Key Information: Only proposals with PI, study site(s), and participants in eligible countries will be considered.